1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025

  • December 2016
  • 102 pages
  • ID: 4584200
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025

Summary

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV) (CDC, 2015; WHO, 2015). HCV can cause both acute and chronic hepatitis infection (WHO, 2015). According to the World Health Organization (WHO), an estimated 130–150 million individuals worldwide are affected with chronic HCV and about 500,000 people died of HCV-related conditions, including liver cirrhosis and hepatocellular carcinoma (HCC), in 2010 (Lozano et al., 2012; WHO, 2015). Acute HCV infection is usually asymptomatic, and out of all people with acute HCV infection, 15–45% of persons spontaneously clear the virus within six months of infection without any treatment (WHO, 2015). About 55–85% of all people infected with HCV develop chronic HCV infection. Of those infected with chronic HCV, risk of developing liver cirrhosis is 15–30% within 20 years (WHO, 2015).

In the 9MM, epidemiologists forecast that the anti-HCV+ total prevalent cases will increase from 19,842,780 total prevalent cases in 2015 to 20,886,113 total prevalent cases in 2025, at an Annual Growth Rate (AGR) of 0.53%. China will have the highest number of anti-HCV+ total prevalent cases among the 9MM throughout the forecast period, while Germany will have the lowest number of anti-HCV+ total prevalent cases.

In the 9MM, epidemiologists forecast that the anti-HCV+ diagnosed prevalent cases will increase from 5,681,205 diagnosed prevalent cases in 2015, to 5,944,944 diagnosed prevalent cases in 2025, at an AGR of 0.46%. China will have the highest number of anti-HCV+ diagnosed prevalent cases among the 9MM throughout the forecast period, while Germany will have the lowest number of anti-HCV+ diagnosed prevalent cases.

The report “EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025” provides an overview of the risk factors, comorbidities, and the global and historical trends for HCV in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China). It includes a 10-year epidemiological forecast of the anti-HCV+ and HCV RNA+ total prevalent cases (including diagnosed and undiagnosed), which are segmented by sex and age (ages 0–19, 20–39, 40–59, 60–79, and 80 years and older). The anti-HCV+ total prevalent cases are further segmented by genotype, human immunodeficiency virus (HIV) comorbidity, and hepatitis B virus (HBV) comorbidity among the 9MM.
Additionally, the report also includes anti- HCV+ and HCV RNA+ diagnosed prevalent cases, which are also segmented by sex and the same age segmentations. The anti-HCV+ diagnosed prevalent cases are segmented by liver cirrhosis status. To forecast the anti-HCV+ total prevalent cases and HCV RNA+ total prevalent cases in the 9MM, epidemiologists used country-specific studies and peer-reviewed journals that provided age- and sex-specific anti-HCV+ total prevalence and HCV RNA+ total prevalence in the respective markets.

Scope

- The Hepatitis C Virus (HCV) EpiCast Report provides an overview of the risk factors and global trends of HCV in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China). It includes a 10-year epidemiological forecast of the anti-HCV+ and HCV RNA+ total prevalent cases (including diagnosed and undiagnosed), which are segmented by sex and age. The anti-HCV+ total prevalent cases are further segmented by genotype, human immunodeficiency virus (HIV) comorbidity, and hepatitis B virus (HBV) comorbidity among the 9MM. Additionally, the report also includes anti-HCV+ and HCV RNA+ diagnosed prevalent cases, which are also segmented by sex and age. The anti-HCV+ diagnosed prevalent cases are segmented by liver cirrhosis status.
- The HCV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

The HCV EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global HCV market.
- Quantify patient populations in the global HCV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCV therapeutics in each of the markets covered.
- Identify the percentage of HCV prevalent cases by genotype, HIV and HBV comorbidity, and liver cirrhosis status.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($3995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
2020 Hepatitis Diagnostics Market: USA, Europe, Japan--Supplier Shares, Test Volume and Sales Forecasts by Country and Market Segment--Hospitals, Blood Banks, Commercial and Public Health Labs, POC Locations

2020 Hepatitis Diagnostics Market: USA, Europe, Japan--Supplier Shares, Test Volume and Sales Forecasts by Country and Market Segment--Hospitals, Blood Banks, Commercial and Public Health Labs, POC Locations

  • $ 4500
  • February 2020

2020 Hepatitis Diagnostics Market: USA, Europe, Japan--Supplier Shares, Test Volume and Sales Forecasts by Country and Market Segment--Hospitals, Blood Banks, Commercial and Public Health Labs, POC LocationsThis ...

Ischemia Reperfusion Injury - Pipeline Review, H1 2020

Ischemia Reperfusion Injury - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Ischemia Reperfusion Injury - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2020, provides an overview ...

2020 Global Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies

2020 Global Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies

  • $ 4500
  • January 2020

2020 Global Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging CompaniesThis unique report provides sales and market share estimates for majo ...


ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on